ERBB2 and breast cancer: Despite no significant differences in DFS and OS between the treatment arms, a nuanced understanding of the protective implications of DDR markers such as ATM and ATR and taxane responsiveness linked to HER2 status highlight their potential roles in refining BC treatment strategies.